<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769170</url>
  </required_header>
  <id_info>
    <org_study_id>CMX001-301</org_study_id>
    <nct_id>NCT01769170</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients</brief_title>
  <official_title>A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared&#xD;
      the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of&#xD;
      cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive&#xD;
      but negative for CMV viremia before starting treatment with BCV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, parallel group multicenter study of&#xD;
      oral brincidofovir (BCV) in approximately 450 cytomegalovirus (CMV)-seropositive subjects who&#xD;
      had undergone allogeneic hematopoietic stem cell transplantation (HCT). The study consisted&#xD;
      of a screening evaluation and a treatment phase of 10 to 14 weeks. Dosing with the study drug&#xD;
      (BCV or placebo) was initiated as soon as individual subjects could ingest tablets after&#xD;
      transplant but no later than Day 28 post-transplant, and was continued through Week 14. All&#xD;
      randomized subjects remained on study and followed the same scheduled study treatment. Study&#xD;
      assessments were performed weekly from randomization through completion of the first&#xD;
      post-treatment follow-up assessment at Week 15, and every 3 weeks thereafter through Week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:&#xD;
Onset of CMV end-organ disease; or&#xD;
Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject.&#xD;
CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant CMV Infection Through Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14.&#xD;
Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>CMV</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered orally twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brincidofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg brincidofovir administered orally twice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brincidofovir</intervention_name>
    <arm_group_label>Brincidofovir</arm_group_label>
    <other_name>BCV</other_name>
    <other_name>CMX001</other_name>
    <other_name>Hexadecyloxypropyl cidofovir</other_name>
    <other_name>HDP-CDV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects were required to meet all of the following criteria, as applicable, to be eligible&#xD;
        to participate in this study:&#xD;
&#xD;
          1. Were allogeneic hematopoietic stem cell transplant (HCT) recipients who had prior&#xD;
             evidence of cytomegalovirus (CMV) exposure (CMV-seropositive) before transplantation&#xD;
             and were CMV viremia negative at screening and at any other assessments performed&#xD;
             prior to the first dose of study drug.&#xD;
&#xD;
          2. Were aged ≥18 years.&#xD;
&#xD;
          3. If male, were willing to use an acceptable contraceptive method(s) throughout the&#xD;
             duration of his participation in the study, i.e., through Week 24, when engaging in&#xD;
             sexual intercourse with a female subject of childbearing potential.&#xD;
&#xD;
          4. If female of childbearing potential, i.e., not postmenopausal or surgically sterile,&#xD;
             were willing to use 2 acceptable contraceptive methods, 1 of which must have been a&#xD;
             barrier method, throughout the duration of her participation in the study, i.e.,&#xD;
             through Week 24, when engaging in sexual intercourse with a nonsterile male partner.&#xD;
&#xD;
          5. Were able to begin study drug dosing within 28 days following the qualifying HCT.&#xD;
&#xD;
          6. Were able to comfortably ingest and absorb oral medication (in the judgment of the&#xD;
             investigator and base don lack of significant gastrointestinal events/medical&#xD;
             history).&#xD;
&#xD;
          7. Were willing and able to understand and provide written informed consent.&#xD;
&#xD;
          8. Were willing and able to participate in all required study activities for the entire&#xD;
             duration of the study (i.e., through Week 24).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects who met any of the following criteria, as applicable, were not eligible to&#xD;
        participate in this study:&#xD;
&#xD;
          1. Was pregnant or planned to become pregnant during the anticipated duration of her&#xD;
             participation in the study (i.e., through Week 24), or was nursing a child.&#xD;
&#xD;
          2. Had a positive CMV viremia test (at the designated central virology laboratory or a&#xD;
             local virology laboratory) at any time between transplant and the first dose of study&#xD;
             drug.&#xD;
&#xD;
          3. Weighed ≥120 kg (~265 lbs).&#xD;
&#xD;
          4. Had hypersensitivity (not renal dysfunction or eye disorder) to cidofovir (CDV),&#xD;
             brincidofovir (BCV), or its excipients.&#xD;
&#xD;
          5. Had received (or were anticipated to need treatment with) any of the following:&#xD;
&#xD;
               -  Ganciclovir, valganciclovir, foscarnet, intravenous CDV, or any other anti-CMV&#xD;
                  therapy (including CMV immune globulin, cell-based therapies, and investigational&#xD;
                  anti-CMV drugs, e.g., leflunomide, letermovir, or maribavir) at any time&#xD;
                  post-transplant;&#xD;
&#xD;
               -  Any anti-CMV vaccine at any time;&#xD;
&#xD;
               -  Any other investigation drug within 14 days prior to the first dose of study drug&#xD;
                  (unless prior approval had been received from the Chimerix medical monitor or&#xD;
                  designee); or&#xD;
&#xD;
               -  Prior treatment with BCV at any time.&#xD;
&#xD;
          6. Were receiving of the following drugs on the first dose of study drug or were&#xD;
             anticipated to receive any of these drugs at the doses described after the first dose&#xD;
             of study drug:&#xD;
&#xD;
               -  Acyclovir orally at &gt;2000 mg total daily dose (TDD) or intravenously at &gt;15 mg/kg&#xD;
                  TDD;&#xD;
&#xD;
               -  Valaciclovir at &gt;3000 mg TDD; or&#xD;
&#xD;
               -  Leflunomide at any dose.&#xD;
&#xD;
          7. Were receiving digoxin or ketoconazole (other than topical formulations) at the first&#xD;
             dose of study drug or were anticipated to need treatment with either digoxin or&#xD;
             ketoconazole during the treatment phase (through Week 14).&#xD;
&#xD;
          8. Had possible, probably, or definitive CMV disease diagnosed within 6 months prior to&#xD;
             first dose of study drug.&#xD;
&#xD;
          9. Were infected with HIV (based on serology), or had an active hepatitis C virus (HCV)&#xD;
             or hepatitis B virus (HBV) infection, as evidence by detectable plasma HCV RNA or HBV&#xD;
             DNA, respectively.&#xD;
&#xD;
         10. Had received another allogeneic HCT (i.e., other than the qualifying HCT) within 2&#xD;
             years prior to the first dose of study drug.&#xD;
&#xD;
         11. Had renal insufficiency, as evidence by an estimated glomerular filtration rate (eGFR)&#xD;
             &lt;15 mL/min or required renal dialysis.&#xD;
&#xD;
         12. Had hepatic abnormalities as evidence by a screening of alanine aminotransferase or&#xD;
             aspartate aminotransferase &gt;5 x the upper limit of normal (ULN), as reported by the&#xD;
             central safety laboratory.&#xD;
&#xD;
         13. Had a screening total bilirubin &gt;2 x the ULN and direct bilirubin &gt;1.5 x the ULN, as&#xD;
             reported by the central safety laboratory.&#xD;
&#xD;
         14. Had active solid tumor malignancies with the exception of basal cell carcinoma or the&#xD;
             underlying condition necessitating HCT (e.g., lymphomas).&#xD;
&#xD;
         15. Had Stage 2 or higher graft versus host disease of the gut or any other GI disease&#xD;
             that would have, in the judgment of the investigator, precluded the subject from&#xD;
             taking or absorbing oral medication (e.g., clinically active Crohn's disease, ischemic&#xD;
             colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any&#xD;
             condition expected to require abdominal surgery during the course of study&#xD;
             participation).&#xD;
&#xD;
         16. Had any other condition, including abnormal laboratory values, that would have, in the&#xD;
             judgement of the investigator, put the subject at increased risk by participating in&#xD;
             the study or would have interfered with the conduct or planned analyses of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego-Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute-Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Universit of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Isreal Decaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College/NY Presbyterial Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute/Carolinas Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sart Tilman Liege</name>
      <address>
        <city>Brüssel</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montreal, Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA, Nichols WG, Boeckh MJ; SUPPRESS Trial Clinical Study Group. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381. doi: 10.1016/j.bbmt.2018.09.038. Epub 2018 Oct 4.</citation>
    <PMID>30292744</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>December 9, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>Hematopoietic Stem Cell Transplant Recipients</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
    <mesh_term>Brincidofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brincidofovir</title>
          <description>100 mg brincidofovir administered orally twice weekly</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo administered orally twice weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat Analysis Set, which included all randomized subjects who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Brincidofovir</title>
          <description>100 mg brincidofovir administered orally twice weekly</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo administered orally twice weekly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="452"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="14.29"/>
                    <measurement group_id="B2" value="51.9" spread="15.03"/>
                    <measurement group_id="B3" value="52.6" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant</title>
        <description>Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:&#xD;
Onset of CMV end-organ disease; or&#xD;
Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject.&#xD;
CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-Treat Analysis Set, which included all subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Brincidofovir</title>
            <description>100 mg brincidofovir administered orally twice weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo administered orally twice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant</title>
          <description>Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:&#xD;
Onset of CMV end-organ disease; or&#xD;
Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject.&#xD;
CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test.</description>
          <population>Intent-to-Treat Analysis Set, which included all subjects who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Clinically Significant CMV Infection Through Week 14</title>
        <description>The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14.&#xD;
Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV.</description>
        <time_frame>14 weeks</time_frame>
        <population>Intention-to-Treat Analysis Set, which included all randomized subjects who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Brincidofovir</title>
            <description>100 mg brincidofovir administered orally twice weekly</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo administered orally twice weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Significant CMV Infection Through Week 14</title>
          <description>The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14.&#xD;
Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV.</description>
          <population>Intention-to-Treat Analysis Set, which included all randomized subjects who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Brincidofovir</title>
          <description>100 mg brincidofovir administered orally twice weekly</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo administered orally twice weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Microangiopathic haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chronic graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Human herpesvirus 6 infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenza viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Viral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Klebsiella test positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Polyomavirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Escherichia test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Citrobacter test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Qt prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Enterococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Human rhinovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pseudomonas test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Plasma cell leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="302" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Within 12 months after the end of the Study at all sites, if no publication of the overall multi-center results has been made, institutions are entitled to publish their locally obtained results, provided the Sponsor is given opportunity to review and comment. Institution publications may be delayed up to an additional 60 days to allow Sponsor to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Chimerix, Inc.</organization>
      <phone>919-806-1074 ext 101</phone>
      <email>dmoore@chimerix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

